Cargando…
Loading, please waitCargando…
Loading, please waitAutoimmune & inflammation cluster
When the immune system mistakes the body's own tissues for a threat, the result is one of more than 80 autoimmune conditions affecting roughly 5% of the global population. Mesenchymal stem cells (MSCs) are studied for their ability to rebalance — not silence — that misdirected response. We apply them as supportive therapy, never as a cure, alongside the rheumatologist, endocrinologist or neurologist already managing your case.
Last medically reviewed · 2026-05-27 · Reviewed by Dra. Claudia Labastida
Regenerative medicine is supportive therapy, complementary to your medical care. Outcomes vary between patients. Every case requires an honest physician evaluation before any treatment is recommended. Regeneris Therapy operates under a COFEPRIS aviso de funcionamiento (2323025036X00098) and only applies protocols backed by clinical evidence for their indications.
Autoimmune disease occurs when the immune system — designed to identify and eliminate foreign invaders such as viruses or bacteria — instead identifies normal cells, tissues or organs as threats and launches a sustained attack against them. Over 80 distinct conditions are currently classified as autoimmune, ranging from organ-specific disorders such as Hashimoto's thyroiditis to systemic conditions such as systemic lupus erythematosus.
Roughly 5% of the global population, and as many as 8% of women, live with an autoimmune diagnosis. The mechanisms are complex and rarely traceable to a single cause — most cases reflect a combination of genetic predisposition, environmental triggers (infections, toxins, chronic stress), gut microbiome disruption and hormonal shifts. The shared denominator across virtually all autoimmune conditions is chronic, low-grade inflammation driven by a dysregulated T-cell and B-cell response.
Conventional treatment relies on disease-modifying antirheumatic drugs (DMARDs), biologics, corticosteroids and immunosuppressants. These are essential and frequently life-saving — but they also carry meaningful long-term burdens, from infection risk to organ toxicity. Regenerative medicine does not replace any of them. It is studied as an adjunct that may help reduce inflammatory load, support immune rebalancing, and improve quality of life within an integrated treatment plan.
MSCs are not a cure. Their relevance in autoimmune medicine is rooted in immunomodulation — the documented capacity to modulate, rather than suppress, the immune response. Published mechanisms include:
MSCs upregulate regulatory T cells (Tregs), the immune system's own brake mechanism, helping to restore tolerance to self-antigens rather than blocking the immune response wholesale.
Dendritic cells present self-tissue as foreign in autoimmunity. MSCs interfere with their maturation, reducing the amplification step that drives autoreactive T-cell expansion.
MSCs secrete soluble factors (IDO, TGF-β, IL-10, prostaglandin E2) that locally damp inflammation, shift macrophages toward a reparative M2 phenotype, and reduce TNF-α and IFN-γ.
MSCs release exosomes carrying microRNAs and proteins that reach distant tissues, contributing to a systemic immunomodulatory effect even after the cells themselves clear circulation.
These mechanisms have been characterized in laboratory and animal models and in early-phase human trials. Clinical translation is real but still maturing. We will say so during your evaluation — and decline to treat you if the evidence does not support a reasonable expectation of benefit for your case.
Each of the conditions below has a dedicated page with mechanism, evidence summary, protocol detail and honest candidacy criteria. The five we have published most thoroughly are also the five with the largest published clinical literature in MSC therapy.
A systemic autoimmune disease that can affect joints, skin, kidneys, blood, brain and other organs. Phase II trials of umbilical-cord MSC infusion in refractory SLE report reductions in SLEDAI activity score, anti-dsDNA titres and steroid dose in selected patients.
Learn about this conditionAn autoimmune demyelinating disease of the central nervous system. MSC therapy is studied in relapsing-remitting and progressive MS for its anti-inflammatory and possible remyelinating effects, alongside disease-modifying therapy (DMTs).
Learn about this conditionAn autoimmune attack on thyroid tissue causing progressive hypothyroidism. MSC and exosome protocols are explored as adjuncts to optimize the inflammatory environment around the thyroid; levothyroxine continues to be the standard of care.
Learn about this conditionWhile not classically autoimmune, fibromyalgia is increasingly characterized as a neuroinflammatory disorder with autoimmune features (small-fibre neuropathy, anti-neuronal antibodies). Small studies of MSC therapy report improvements in pain, fatigue and sleep quality.
Learn about this conditionType 2 diabetes is a metabolic disease with a significant chronic-inflammatory component that drives insulin resistance and β-cell stress. Phase II trials of MSC infusion report improvements in HbA1c, C-peptide and insulin sensitivity — never as a replacement for medication or lifestyle change.
Learn about this conditionThe MSC literature extends beyond our five published condition pages. We evaluate the following on a case-by-case basis, openly disclosing the strength of the evidence and the experimental nature of the protocol:
Phase I/II trials of umbilical-cord MSC infusion in RA report reductions in DAS-28 score, swollen-joint count and CRP. We coordinate with your rheumatologist and your current DMARD/biologic regimen — never as replacement.
MSC therapy has the strongest IBD evidence in perianal fistulizing Crohn's disease (where allogeneic MSC product Alofisel is regulator-approved in Europe). Systemic IV protocols for active luminal disease remain investigational.
Small-scale studies of MSC therapy in systemic sclerosis report improvements in skin score and pulmonary function in selected patients. We treat very conservatively here and require a recent specialist evaluation before considering candidacy.
Each has a small but growing MSC literature. We evaluate candidacy honestly, frequently decline cases where evidence is thin, and never market these as established indications.
We rely on peer-reviewed literature and registered trials — not testimonials. The strongest evidence base for MSC therapy across the autoimmune spectrum is concentrated in three indications:
Multiple phase II trials of umbilical-cord MSC infusion in refractory SLE (notably Sun L. et al, Drum Tower Hospital Nanjing cohorts) report reductions in disease activity scores, anti-dsDNA, complement normalization and steroid sparing. Effects are not universal and are most consistent in younger patients with active immune dysregulation rather than end-stage organ damage.
Phase I/II trials of autologous bone-marrow and umbilical-cord MSC therapy in MS (e.g. Karussis et al., the MESEMS consortium) consistently demonstrate safety. Efficacy signals on EDSS progression and MRI lesion activity are mixed but positive in selected relapsing-remitting cohorts. MSC therapy is studied as adjunct, not replacement, for DMTs.
Phase II RCTs of umbilical-cord MSC IV infusion in T2D (e.g. Hu et al., Cao et al.) report sustained reductions in HbA1c and daily insulin requirement at 12-month follow-up in patients with preserved residual β-cell function. Effects do not reverse advanced diabetes nor replace lifestyle and medication.
We do not cite case reports, single-arm pilot studies without follow-up, or industry-funded white papers as evidence of efficacy. When a query reaches an indication where the literature does not yet support honest recommendation, we say so.
Our medical team applies the same screening criteria across every autoimmune indication:
A typical autoimmune MSC protocol at Regeneris Therapy follows a personalized version of the structure below. Dose, source (umbilical cord, allogeneic) and adjuncts are tailored to your indication and physician assessment.
Full clinical history, current medications, disease-specific activity score and recent labs are reviewed. Treatment is recommended only if criteria are met.
Slow intravenous infusion of allogeneic umbilical-cord-derived MSCs in a sterile, COFEPRIS-regulated setting. Sessions last 2 to 4 hours under physician monitoring.
Targeted IV therapy (NAD+, glutathione, vitamin and mineral repletion) supports the inflammatory and metabolic environment in which the infused MSCs operate.
Structured follow-up appointments coordinate findings with your treating specialist and update labs to track activity scores, CRP and disease-specific biomarkers.
We use language carefully because autoimmune patients are routinely promised cures by less honest clinics. What MSC therapy may realistically contribute, when the indication and timing are right:
MSC therapy is not a cure for any autoimmune disease. Anyone promising one is misleading you. The same is true for any clinic that offers MSC therapy without continued coordination with your rheumatologist, endocrinologist or neurologist.
We turn down cases routinely when the evidence or the safety profile does not support treatment:
The eight questions below come from real intake conversations and are answered honestly by our medical team.
No. There is currently no cure for autoimmune disease — only management. MSC therapy is studied as an adjunct that may modulate the immune response and reduce inflammatory load alongside your specialist's treatment. Any clinic promising a cure is misleading you.
No, and you should not. Continuing your specialist's prescriptions is a precondition of treatment with us. We coordinate timing of the MSC infusion with your current regimen — never replace it.
We have published condition-specific pages for systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, fibromyalgia and type 2 diabetes. We treat rheumatoid arthritis, IBD, scleroderma and others on a case-by-case basis after careful candidacy review.
Inflammatory markers (CRP, ESR) and patient-reported symptoms (fatigue, sleep, pain) commonly show change between weeks 4 and 12. Disease-specific activity scores often require 3 to 6 months and a structured follow-up cycle with your specialist to capture meaningfully.
Polyautoimmunity is common and not an exclusion criterion in itself. Our consultation reviews disease activity for each condition and identifies which is the leading driver. The same MSC protocol typically modulates the shared inflammatory pathways.
Regeneris Therapy operates under a COFEPRIS aviso de funcionamiento (2323025036X00098) and a COFEPRIS advertising notice (2323022002A00053). Cellular products are sourced from COFEPRIS-licensed laboratories with full donor-to-application traceability.
Cost is communicated transparently after the medical consultation, when the physician has confirmed candidacy and designed the personalized protocol. We do not quote prices before evaluation because the appropriate dose and adjuncts vary materially between cases.
We will tell you honestly and explain the clinical reason. When possible, we redirect to a more appropriate care path — your specialist, a non-MSC supportive option, or a clinical trial where the evidence is stronger for your specific condition.
Book a free 15-min call with our team.
Next step
Every autoimmune treatment plan begins with a coordinated medical consultation. Bring your specialist's recent notes, your current medications and your most recent labs. We will give you an honest answer — including a redirection if MSC therapy is not the right fit for you.